Muñoz-Estrada VF, Maldonado-Domínguez ED, Almeida-Vega W, Meza-Machado L

Idioma: Español
Referencias bibliográficas: 120
Paginas: 263-283
Archivo PDF: 457.39 Kb.

RESUMEN

La talidomida es un fármaco con una historia impactante en la medicina y que causó desastres en gran parte de la población, ya que fue administrada a las personas incorrectas, sin embargo, a lo largo del tiempo se ha reposicionado y en la actualidad se utiliza en múltiples patologías dermatológicas, con resultados terapéuticos excelentes debido a sus propiedades antiinflamatorias, antiangiogénicas e inmunomoduladoras. El objetivo de esta revisión es describir la histo-ria, farmacología, mecanismo de acción, indicaciones en Dermatología y efectos adversos de la talidomida. Obteniendo como resultado que la talidomida tiene múltiples indicaciones en enfermedades dermatológicas así como en otras áreas de la salud.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci 2020; 96(6):189-203.

2. McBride WG. Thalidomide embryopathy. Teratology 1977; 16(1):79-82.

3. Mellin GW. Katzenstein M. The saga of tha-lidomide. Neuropathy to embryopathy, withcase reports of congenital anomalies. N Engl J Med 1962; 267:1238-44 concl.

4. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6:303-6.

5. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degrada-tion. J Exp Med 1993; 177(6):1675-80.

6. Zafra M, García NVM. Enfermedades pediá-tricas que han pasado a la historia (10). Sín-drome de la talidomida: descubrimiento, tra-gedia y enseñanzas. Pediatr Integral 2022; XXVI (4): 259.e1–259.e9.

7. Vargesson N. Thalidomide Embryopathy: An Enigmatic Challenge. ISRN 2013; vol. 2013, Article ID 241016: 1-18.

8. Martínez-Frías ML. Talidomida: 50 años después. Med Clin (Barc) 2012; 139(1):25-32.

9. Lenz W. A short history of thalidomide embr-yopathy. Teratology 1988; 38(3):203-15.

10. Moro A, Invernizzi N. The thalidomide tra-gedy: the struggle for victims' rights and im-proved pharmaceutical regulation. Hist Cienc Saude Manguinhos 2017; 24(3):603-622.

11. García NVM. ¿Quién fue Wiedemann? Hu-manidades en Pediatría. Epónimos en Pe-diatría. Canar Ped 2008; 32: 141-3.

12. Rosenbach M, Werth VP. Dermatologic the-rapeutics: thalidomide. A practical guide. Dermatol Ther 2007; 20(4):175-86.

13. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969; 37(2):135-

14. Mascaro JM, Lecha M, Torras H. Thalido-mide in the treatment of recurrent, necrotic,and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979; 115(5):636-7.

15. Gutiérrez-Rodríguez O. Thalidomide. A pro-mising new treatment for rheumatoid arthri-tis. Arthritis Rheum 1984; 27(10):1118-21.

16. Vogelsang GB, Farmer ER, Hess AD, Alta-monte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326(16):1055-8.

17. Papaseit E, Farré M, Garcia-Algar Ó. Thali-domide, the story goes on. An Pediatr (Engl Ed) 2023; 98(6):490-491.

18. Singhal S, Mehta J, Desikan R, Ayers D, Ro-berson P, Eddlemon P, Munshi N, et al. An-titumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341(21):1565-71.

19. Vargesson N. The teratogenic effects of tha-lidomide on limbs. J Hand Surg Eur Vol 2019; 44(1):88-95.

20. Li Y, Shi K, Qi F, Yu Z, Chen C, Pan J, et al. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. Int J Infect Dis 2021; 103:507-513.

21. Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, et al. Clinical pharmacokinetics of thalidomide. Clin Phar-macokinet 2004; 43(5):311-27

22. Chen TL, Vogelsang GB, Petty BG, Brun-drett RB, Noe DA, Santos GW, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989; 17(4):402-5.

23. Yang CS, Kim C, Antaya RJ. Review of tha-lidomide use in the pediatric population. J Am Acad Dermatol 2015; 72(4):703-11.

24. Czejka MJ, Koch HP. Determination of thali-domide and its major metabolites by high-performance liquid chromatography. J Chro-matogr 1987; 413:181-7.

25. Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD. Metabolism of thalidomide in human microsomes, cloned human cytoch-rome P-450 isozymes, and Hansen's di-sease patients. J Biochem Mol Toxicol 2000; 14(3):140-7.

26. Franks ME, Macpherson GR, Figg WD. Tha-lidomide. Lancet 2004; 363(9423):1802-11.

27. Vargesson N, Stephens T. Thalidomide: his-tory, withdrawal, renaissance, and safety concerns. Expert Opin Drug Saf 2021; 20(12):1455-1457.

28. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173(3):699-703.

29. Lee HS, Kwon HS, Park DE, Woo YD, Kim HY, Kim HR. Thalidomide inhibits alternative activation of macrophages in vivo and in vi-tro: a potential mechanism of anti-asthmatic effect of thalidomide. PLoS One 2015; 10(4):e0123094.

30. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thali-domide. BioDrugs 2001; 15(10):681-703.

31. D'Amato RJ, Loughnan MS, Flynn E, Folk-man J. Thalidomide is an inhibitor of angio-genesis. Proc Natl Acad Sci USA 1994; 91(9):4082-5.

32. Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 2003; 12(7):1211-25.

33. Fernández-Ponce C, Hernández-Martínez JD, Silvera-Redondo C. Ctla-4, una molé-cula que inhibe la activación de los linfocitos T. Salud Uninorte 2006; 22(2):168-181.

34. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing prolife-ration, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187(11):1885-92.

35. Domingo S, Solé C, Moliné T, Ferrer B, Ordi-Ros J, Cortés-Hernández J. Efficacy of Tha-lidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. Dermatology 2020; 236(5):467-476.

36. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327(5971):1345-50.

37. Asatsuma-Okumura T, Ito T, Handa H. Mo-lecular mechanisms of cereblon-based drugs. Pharmacol Ther 2019; 202:132-139.

38. Hinoshita F. 2020 Guide for the manage-ment of thalidomide embryopathy. Tokyo (Japan): Center Hospital of the National Center for Global Health and Medicine (NCGM); 2021. http:// thalidomide-embryo-pathy.com/common/ data/pdf/guide_2020_en.pdf

39. Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016; 95(30):e4239.

40. Barlogie B, Tricot G, Anaissie E. Thalido-mide in the management of multiple myeloma. Semin Oncol 2001; 28(6):577-82.

41. Lau CB, Smith GP. Recurrent aphthous sto-matitis: A comprehensive review and recom-mendations on therapeutic options. Derma-tol Ther 2022; 35(6):e15500.

42. Eatmann AI, Hamouda E, Hamouda H, Fa-rouk HK, Jobran AWM, Omar AA, et al. Po-tential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. Me-tabolites 2023; 13(4):543.

43. Reyes-Terán G, Sierra-Madero JG, Martí-nez del Cerro V, Arroyo-Figueroa H, Pas-quetti A, Calva JJ et al. Effects of thalido-mide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-contro-lled clinical trial. AIDS 1996; 10(13):1501-7.

44. Rubegni P, Sbano P, De Aloe G, Flori ML, Fimiani M. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology 2007; 215(3):240-4.

45. Fang J, Chen X, Zhu B, Ye H, Zhang W, Guan J, et al. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telan-giectasia: A Preliminary Study. Otolaryngol Head Neck Surg 2017; 157(2):217-221.

46. Millrine D, Kishimoto T. A Brighter Side to Thalidomide: Its Potential Use in Immunolo-gical Disorders. Trends Mol Med 2017; 23(4):348-361.

47. Uhl K, Cox E, Rogan R, Zeldis JB, Hixon D, Furlong LA, et al. Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 2006; 29(4):321-9.

48. Costa PDSS, Fraga LR, Kowalski TW, Daxbacher ELR, Schuler-Faccini L, Vianna FS. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglec-ted condition. Acta Trop 2018; 183:134-141.

49. Hassan I, Dorjay K, Anwar P. Thalidomide in dermatology: revisited. Indian J Dermatol 2015; 60(2):213.

50. Iyer CG, Languillon J, Ramanujam K, Tara-bini-Castellani G, De las Aguas JT, Bechelli LM, et al. WHO co-ordinated short-term dou-ble-blind trial with thalidomide in the treat-ment of acute lepra reactions in male lepro-matous patients. Bull World Health Organ 1971; 45(6):719-32.

51. Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, et al. Thalidomide in the treatment of leprosy. Microbes Infect 2002; 4(11):1193-202.

52. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' expe-rience with thalidomide. Int J Dermatol 1980; 19(6):318-22.

53. Kaur I, Dogra S, Narang T, De D. Compara-tive efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. Australas J Dermatol 2009; 50(3):181-5.

54. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol. 1973; 12(5):326-8.

55. Lovell CR, Hawk JL, Calnan CD, Magnus IA. Thalidomide in actinic prurigo. Br J Derma-tol. 1983; 108(4):467-71.

56. Leis M, Fleming P, Lynde CW. Prurigo No-dularis: Review and Emerging Treatments. Skin Therapy Lett 2021; 26(3):5-8.

57. Sardana K, Gupta A, Sinha S. An observa-tional analysis of low-dose thalidomide in re-calcitrant prurigo nodularis. Clin Exp Derma-tol 2020; 45(1):92-96.

58. Aguh C, Kwatra SG, He A, Okoye GA. Tha-lidomide for the treatment of chronic refrac-tory prurigo nodularis. Dermatol Online J 2018; 24(3):13030/qt44n0k1xm.

59. Andersen TP, Fogh K. Thalidomide in 42 pa-tients with prurigo nodularis Hyde. Dermato-logy 2011; 223(2):107-12

60. Bowers PW, Powell RJ. Effect of thalidomide on orogenital ulceration. Br Med J (Clin Res Ed) 1983; 287(6395):799-800.

61. Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, et al. Crossover study of thalidomide vs placebo in severe re-current aphthous stomatitis. Arch Dermatol 1990; 126(7):923-7.

62. Deng Y, Wei W, Wang Y, Pan L, Du G, Yao H, et al. A Randomized controlled clinical trial on dose optimization of thalidomide inmaintenance treatment for recurrent aphthous stomatitis. J Oral Pathol Med 2022; 51(1):106-112.

63. Garza-Mayers AC, McClurkin M, Smith GP. Review of treatment for discoid lupus erythe-matosus. Dermatol Ther 2016; 29(4):274-83.

64. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to anti-malarial agents in cutaneous lupus erythe-matosus: a prospective analysis. Arch Der-matol 2011; 147(11):1261-7.

65. Volc-Platzer B, Wolff K. Treatment of subacute cutaneous lupus erythematosus with thalidomide. Hautarzt 1983; 34(4):175-8.

66. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lu-pus erythematosus. Br J Dermatol 1983; 108(4):461-6.

67. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Arch Dermatol 1983; 119(10):812-5.

68. Chasset F, Tounsi T, Cesbron E, Barbaud A, Francès C, Arnaud L. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. J Am Acad Dermatol 2018; 78(2):342-350.e4.

69. Tirado-Sánchez A, Aguilar-Mena C, Rodri-guez-Mendoza A, Hernández-Salgado Y, Bonifaz A. Clinical-therapeutic study on the efficacy and safety of thalidomide in the ma-nagement of discoid lupus erythematosus. A single-centre, retrospective study. Australas J Dermatol 2021; 62(3):375-379.

70. Baret I, De Haes P. Thalidomide: Still an im-portant second-line treatment in refractory cutaneous lupus erythematosus?. J Derma-tolog Treat 2015; 26(2):173-7.

71. Cortés-Hernández J, Torres-Salido M, Cas-tro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012; 166(3):616-23.

72. Kyriakis KP, Kontochristopoulos GJ, Pante-leos DN. Experience with low-dose thalido-mide therapy in chronic discoid lupus erythe-matosus. Int J Dermatol 2000; 39(3):218-22.

73. Alibaz-Oner F, Direskeneli H. Update on the Diagnosis of Behcet's Disease. Diagnostics (Basel) 2022; 13(1):41.

74. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, dou-ble-blind, placebo-controlled trial. Ann Intern Med 1998; 128(6):443-50.

75. Shek LP, Lim DL. Thalidomide in Behcet's disease. Biomed Pharmacother 2002; 56(1):31-5.

76. Saylan T, Saltik I. Thalidomide in the treat-ment of Behçet's syndrome. Arch Dermatol 1982; 118(8):536.

77. Trayes KP, Love G, Studdiford JS. Erythema Multiforme: Recognition and Management. Am Fam Physician 2019; 100(2):82-88.

78. Conejo-Mir JS, del Canto S, Muñoz MA, Ro-dríguez-Freire L, Serrano A, Hernandez C, et al. Thalidomide as elective treatment in persistent erythema multiforme; report of two cases. J Drugs Dermatol 2003; 2(1):40-4.

79. Roux C, Sbidian E, Bouaziz JD, Kottler D, Joly P, Descamps V, et al. Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study. JAMA Derma-tol 2021; 157(12):1472-1476.

80. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G, et al. Thalidomide induces granuloma diffe-rentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002; 102(3):225-36.

81. Carlesimo M, Giustini S, Rossi A, Bonac-corsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32(5 Pt 2):866-9.

82. Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, et al. A randomized, in-vestigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cu-taneous sarcoidosis. Chest 2014; 146(4):1046-1054.

83. George C, Deroide F, Rustin M. Pyoderma gangrenosum - a guide to diagnosis and ma-nagement. Clin Med (Lond) 2019; 19(3):224-228.

84. Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thali-domide. Mayo Clin Proc 2000; 75(8):842-4.

85. Hecker MS, Lebwohl MG. Recalcitrant pyo-derma gangrenosum: treatment with thalido-mide. J Am Acad Dermatol 1998; 38(3):490-1.

86. Hauser C, Schifferli J, Saurat JH. Comple-ment consumption in a patient with necrobio-tic xanthogranuloma and paraproteinemia. J Am Acad Dermatol 1991; 24(5 Pt 2):908-11.

87. Efebera Y, Blanchard E, Allam C, Han A, Lee S, Munshi N. Complete response to tha-lidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associa-ted with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 2011; 11(3):298-302.

88. Kukreja T, Petersen J. Thalidomide for the treatment of refractory necrobiosis lipoidica. Arch Dermatol 2006; 142(1):20-2.

89. Shah SD, Kale GV. Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with oral thalidomide. Indian Dermatol On-line J 2016; 7(1):43-5.

90. Kim JH, Kim SC. Paraneoplastic Pemphi-gus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa. Front Immunol 2019; 10:1259.

91. Wang J, Zhang Y, Pan M. Thalidomide as a potential adjuvant treatment for paraneo-plastic pemphigus: A single-center expe-rience. Dermatol Ther 2020; 33(6):e14353.

92. Solèr RA, Howard M, Brink NS, et al. Re-gression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996; 23(3):501-3; discussion 504-5.

93. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sar-coma and correlation with HHV8 titre. Int J STD AIDS 1998; 9(12):751-5.

94. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thali-domide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18(13):2593-602.

95. Wolk Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Ran-domised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lan-cet 1998; 352(9140):1586-9.

96. Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalido-mide. Arch Dermatol 2000; 136(12):1442-3.

97. Moura AK, Moure ER, Romiti R. Treatment of cutaneous lichen planus with thalidomide. Clin Exp Dermatol 2009; 34(1):101-3.

98. George SJ, Hsu S. Lichen planopilaris treated with thalidomide. J Am Acad Derma-tol 2001; 45(6):965-6.

99. Saurat JH, Camenzind M, Helg C, Chapuis B. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1988; 1(8577):117.

100. Oliver SJ, Moreira A, Kaplan G. Immune sti-mulation in scleroderma patients treated with thalidomide. Clin Immunol 2000; 97(2):109-20.

101. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004; 140(3):277-80.

102. Sansbury JC, Cocuroccia B, Jorizzo JL, Gu-binelli E, Gisondi P, Girolomoni G. Treat-ment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Derma-tol 2004; 51(1):126-31.

103. Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology. Clin Exp Der-matol 2022; 47(4):667-674.

104. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153(2):254-73.

105. Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, et al. Thalido-mide dose proportionality assessment follo-wing single doses to healthy subjects. J Clin Pharmacol 2001; 41(6):662-7.

106. Kumar S, Witzig TE, Rajkumar SV. Thalido-mide as an anti-cancer agent. J Cell Mol Med 2002; 6(2):160-74.

107. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, et al. Pharmacokine-tics of thalidomide in an elderly prostate can-cer population. J Pharm Sci 1999; 88(1):121-5.

108. Bishnoi A, Singh V, Handa S, Vinay K. Tha-lidomide and thromboprophylaxis for derma-tologic indications: An unmet need for more evidence. J Am Acad Dermatol 2018; 79(3):e45-e46.

109. Cundari S, Cavaletti G. Thalidomide chemo-therapy-induced peripheral neuropathy: ac-tual status and new perspectives with thali-domide analogues derivatives. Mini Rev Med Chem 2009; 9(7):760-8.

110. Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus. J Am Acad Dermatol 2016; 74(2):363-9.

111. Phan A, Favrole P, Alamowitch S, Chosidow O. Thalidomide-related headache. Dermato-logy 2009; 218(3):285.

112. Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010; 28(3):577-86.

113. Teo SK, Harden JL, Burke AB, Noormoha-med FH, Youle M, Johnson MA, et al. Thali-domide is distributed into human semen af-ter oral dosing. Drug Metab Dispos 2001; 29(10):1355-7.

114. Newman CG. Teratogen update: clinical as-pects of thalidomide embryopathy--a conti-nuing preoccupation. Teratology 1985; 32(1):133-44.

115. Smithells RW, Newman CG. Recognition of thalidomide defects. J Med Genet 1992; 29(10):716-23.

116. Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalido-mide. Postgrad Med J 1994; 70(830):901-4.

117. Bahmer FA, Zaun H, Luszpinski P. Thalido-mide treatment of recurrent erythema multi-forme. Acta Derm Venereol 1982; 62(5):449-50.

118. Barriere H. Cutaneous sarcoidosis. Treat-ment with thalidomide. Presse Med 1983; 12(15):963.

119. Venencie PY, Saurat JH. Pyoderma gangre-nosum in a child. Treatment with thalidomide (author's transl). Ann Pediatr (Paris) 1982; 29(1):67-9.

120. Pérez-Alfonzo R, Weiss E, Piquero-Martín J, Rondón-Lugo A. Generalized lichen planus with erosive lesions of the penis, treated with thalidomide. Report of a case and review of the literature. Med Cutan Ibero Lat Am 1987; 15(4):321-6.